07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Action Pharma, Zealand Pharma, Abbott deal

Abbott completed the acquisition of AP214 and related IP from Action following the receipt of U.S. Antitrust clearance. Last year, the alpha-melanocyte-stimulating hormone analog met the primary endpoint in a Phase IIb trial to prevent...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Action Pharma, Zealand Pharma, Abbott deal

Abbott will acquire AP214 and related IP from Action Pharma for $110 million in cash. Last year, AP214 met the primary endpoint in a Phase IIb trial to prevent post-surgical kidney injury following cardiac surgery...
07:00 , May 7, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $1.33 (11%) to $13.77 last week after FDA accepted for review an NDA for lomitapide to treat homozygous familial hypercholesterolemia. The PDUFA date is Dec. 29. Alexza Pharmaceuticals...
00:39 , May 4, 2012 |  BC Extra  |  Company News

Abbott buys Action's AP214

Abbott Laboratories (NYSE:ABT) will acquire AP214 and related IP from Action Pharma A/S (Aarhus, Denmark) for $110 million in cash. Last year, AP214 met the primary endpoint in a Phase IIb trial to prevent post-surgical...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Clinical News

AP214: Phase IIb data

Top-line data from a double-blind, U.S. and Danish Phase IIb trial in 77 patients undergoing cardiac surgery with cardiopulmonary bypass showed that AP214 met the primary endpoint of achieving significantly lower creatinine levels at day...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

AP214: Phase IIb started

Action Pharma began a double-blind, placebo-controlled, U.S. and Danish Phase IIb trial to evaluate 2 doses of AP214 given 3 times as a bolus injection in 75 patients undergoing cardiac surgery under cardiopulmonary bypass. Action...
07:00 , Jun 21, 2010 |  BC Week In Review  |  Clinical News

AP214: Interim Phase II data

Interim data from a double-blind, placebo-controlled, Danish Phase II trial in 42 patients showed that 10, 50 and 200 µg/kg doses of IV AP214 were well tolerated. At the highest dose, AP214 prevented increases in...
07:00 , Jun 7, 2010 |  BC Week In Review  |  Financial News

Action Pharma completes venture financing

Action Pharma A/S , Holte, Denmark   Business: Metabolic, Endocrine, Autoimmune   Date completed: 6/3/10   Type: Venture financing   Raised: €5 million ($6.1 million)   Investors: Sunstone; Global Life Science Ventures; SLS Invest AB;...
07:00 , May 31, 2010 |  BioCentury  |  Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Clinical News

AP214: Phase II completed

Action Pharma completed enrollment and dosing of 42 patients in a double-blind, placebo-controlled, Danish Phase II trial evaluating intravenous AP214. The company licensed worldwide rights to develop and commercialize AP214 from Zealand Pharma in 2003....